Cholesterol
Pregnenolone
Progesterone
Corticosterone
17α-OH-
pregnenolone
DHEA
Androstenedione
Testosterone
17α –OH-
progesterone
Cortisol
Aldosterone
Deoxy-corticosterone
DHT
5α-reductase
11-Deoxy-cortisol
CYP19: aromatase
Estradiol
Desmolase
Renin
11β-Hydroxylase
CYP17
17α-
hydroxylase
CYP17
C17,20-
lyase
Inhibidor selectivo e irreversible de CYP17
Inhibe síntesis de andrógenos en las glándulas suprarrenales, testículos
y próstata
,1,2
Suprime andrógenos séricos hasta niveles indetectables
y de las células prostáticas
3,4
Débil efecto anti-androgénico
1. Hofland J et al. Cancer Res 2010; 70:1256-1264. 2. Chen Y et al. Lancet Oncol 2009; 10 (10): p981-91. 3. Hoimes CJ, Kelly WK. Redefining hormone resiste in prostate cancer. Ther Adv Med Oncol. 2010;2(2):107-123. 4. Scher, H.I. et al.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Eworking Group. J Clin Oncol. 2008;26(7): 1148-59. 8. Agarwal,
N. et al. Abiraterone Acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol. 2010;6(5):665-79. .
Abiraterona:
mecanismo de acción
AA
